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Abstract
Background: Taiwan's national vaccination program has successfully decreased the prevalence of
hepatitis B infection after twenty years of implementation and might be indirectly beneficial to the
second generation. In this study, we compared the hepatitis B infection status of two groups:
pregnant Taiwanese women and other Southeast Asian women, who because they had immigrated
later in life to Taiwan by marriage to a Taiwanese man, had not been exposed to that vaccination
program to evaluate the effect of hepatitis vaccination program on women of child-bearing age and
further explored the potential impact of immigration on the hepatitis B public health policy in
Taiwan.
Methods: Data was collected from 10,327 women born in Taiwan and 1,418 women born in other
Southeast Asian countries, both groups receiving prenatal examinations at Fooyin University
Hospital between 1996 and 2005. The results of serum hepatitis B s-Antigen (HBsAg) and hepatitis
B e-Antigen (HBeAg) tests and other demographic data were obtained by medical chart review.
Results: The pregnant women from Taiwan had a higher HBsAg positive rate (15.5%) but lower
HBeAg(+)/HBsAg(+) ratio (32.1%) than the women from other countries (8.9% and 52.4%). For
those born before July, 1984, the period of no national vaccination program, Taiwanese women
had a higher HBsAg positive rate than other Southeast Asian women (15.7% vs. 8.4%), but for
women born after that day and before June 1986, the period of vaccination for high risk newborns,
the HBsAg positive rates found to be slightly lower for Taiwanese women than for other Southeast
Asian women (11.4% vs. 12.3%) and the difference was more significant (3.1% vs. 28.6%) after June
1986, the period of vaccination for all newborns. While the HBeAg(+)/HBsAg(+) ratios decreased
with age in both groups, they were consistently higher in women from other Southeast Asian
countries than in women born in Taiwan after age 20.
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Conclusion: In Taiwan, the neonatal vaccination program that was implemented in 1984 has
successfully reduced hepatitis B infection among pregnant women in present day, and is likely to
indirectly prevent hepatitis B infection in the next generation. However, the increasing number of
pregnant women from other Southeast Asian countries without a national neonatal vaccination
program or with a program that was introduced later than the one in Taiwan will likely lessen the
positive impact of this program and should be further assessed.
Background
There are estimated 350 million people infected with
Hepatitis B Virus (HBV) worldwide. While prevalence var-
ies widely, it is especially high in Taiwan and other Asian
countries [1]. HBV has been associated with hepatocellu-
lar carcinoma, the second most common cancer, and cir-
rhosis and chronic hepatitis, the seventh leading cause of
death in Taiwan in 2004 [2-4].
Based on the results of Beasley et al's randomized blind
controlled trial demonstrating the effectiveness of hepati-
tis B vaccine in preventing perinatal HBV infection, Tai-
wan became one of the first countries to introduce a
national HBV vaccination program in July 1984 [4,5].
During the first two years of the program, only newborns
born to mothers found positive for HBsAg received vacci-
nations; after June, 1986, coverage was further extended
to all newborns [4]. The coverage rates of HBV vaccine for
the target population were all more than 90% since the
initiation of the program in 1984 [4]. This program has
successfully reduced the prevalence of hepatitis B in chil-
dren and the incidence of hepatocellular carcinoma in
those exposed to the vaccine [1,6,7]. After two decades,
with these vaccinated women now at child-bearing age,
the benefits of this vaccination program may soon be seen
in the second generation.
One possible threat to the completeness of is program is
recent interest of Taiwanese men in marrying women
from Southeast Asian countries, where prevalence of hep-
atitis B is also high but there has been no similar hepatitis
vaccination program in place [8]. This study investigated
hepatitis B infection status among pregnant Taiwanese
women and pregnant women from five Southeast Asian
countries across three periods of different hepatitis B vac-
cine programs in Taiwan (no vaccination, vaccination for
high risk newborns and vaccination for all newborns) to
evaluate the effect of hepatitis B vaccination program on
women of child-bearing age in Taiwan and further explore
the potential impact of immigration on the Hepatitis B
public health policy in Taiwan.
Methods
We recruited 11,745 pregnant women, 10,327 women
from Taiwan and 1,418 women from five Southeast Asian
countries (Philippines, Cambodia, Indonesia, Thailand,
and Vietnam), all receiving routine prenatal examinations
at Fooyin University Hospital between 1996 and 2005.
This regional hospital provides obstetric health care to
several townships in Pingtong, Taiwan.
Blood samples were obtained from all participants during
the early second trimester and tested for the hepatitis B s-
Antigen (HBsAg) and hepatitis B e-Antigen (HBeAg). The
serologic antigens were analyzed by Microparticle Enzyme
Immunoassay (MEIA) method using AxSYM (Abbot Lab-
oratories, Chicago, Illinois, USA) HBsAg (V2) and HBeAg
2.0 kits. Data on age, nationality, and HBsAg and HBeAg
tests were collected retrospectively by reviewing the med-
ical records of these women. This protocol for study was
approved by Fooyin University Hospital's IRB. All per-
sonal information was removed, making it impossible to
link a participant's individual information without fur-
ther permission from the hospital.
The participants were first categorized by nationality
groups and sub-categorized by specific time periods. Age
was expressed as mean ± 1SD for women from Taiwan
and the five other countries. We compared the differences
between women from Taiwan and other five countries
using chi-square test or fisher's exact test for those with
small sample size, and calculated the odds ratio (OR) for
a positive HBsAg rate for these women and the OR for a
positive HBeAg rate among HBsAg(+) women. We further
conducted the analyses stratified by age and date of birth.
In order to compare the HBsAg positive rates over time
and under different coverage strategies (no vaccination,
vaccination for newborns of high risk and vaccination for
all newborns), we stratified our data by relevant time peri-
ods. The p-value < 0.05 was considered as significant. All
statistical operations were performed using SAS software
(version 9.12 ; SAS Institute, Cary, NC).
Results
From 1996 to 2005, 11,745 pregnant women, including
10,327 Taiwanese women, 1,114 from Vietnam, 171 from
Indonesia, 71 women from the Philippines, 42 from
Cambodia, and 20 from Thailand received routine prena-
tal examinations at Fooyin University Hospital. The
number and percentages of pregnant Southeast Asian
women seeking prenatal examinations in this hospital
increased from 50 women (1.2% of the total) betweenBMC Public Health 2008, 8:49 http://www.biomedcentral.com/1471-2458/8/49
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1996 and 1999 to 919 (24.6% of the total) between 2003
and 2005 (Table 1). The average prevalence rate of hepa-
titis B among Taiwanese women was 15.5% and among
Southeast Asian women 8.9% (9.5% for Cambodia, 9.0%
for Philippines, 8.9% for Vietnam, 8.8% for Indonesia,
and 5.5% for Thailand).
Women born in Taiwan appeared to be older than the
women from the five other countries (26.0 years vs. 23.4
years). Taiwanese women also had significantly higher
HBsAg positive rates (15.5% vs. 8.9%) but lower
HBeAg(+)/HBsAg(+) ratios (32.1% vs. 52.4%). Table 2
presents the differences in HBsAg positive rates between
Taiwanese women and other Asian women stratified by
age and date of birth. Taiwanese women seemed to have
higher HBsAg positive rates (15.5% vs. 8.9%). However,
the declining trend in seropositive rates over age and time
period was only observed in Taiwanese women, for
whom, the rates decreased from 16.6 % for the women
aged >30 years to 12.8% for those aged 20 years, and
decreased from 15.7% for women born before July 1984,
11.4% for those born between July1984 and June 1986, to
3.1% for those born after June 1986. Taiwanese women
born after implementation of the vaccine program had
lower HBsAg positive rate than women born outside of
Taiwan (8.8% vs. 13.1%). For those born after June 1986,
the date of initiation of coverage for all newborns, the
seropositive rate among Taiwanese women even
decreased into 3.1% while the rate in women from the five
other countries was 28.6% and the odds ratio was 12.4
(95% CI: 1.67–91.9) with p-value of 0.04.
Table 3 presents the differences in HBeAg(+)/HBsAg(+)
ratios between Taiwanese women and other Asian women
stratified by age and date of birth. Taiwanese women had
significantly lower HBeAg(+)/HBsAg(+) ratios (32.1% vs.
Table 1: Numbers and HBsAg positive rates of pregnant women born in Taiwan and other six Southeast Asian countries from 1996 to 
2005
Taiwan Other South East Asia countries
All countries Philippines Cambodia Indonesia Thailand Vietnam
Number of women
1996–1999 4206 50 24 3 12 5 6
2000–2002 3305 449 33 23 87 6 300
2003–2005 2816 919 14 16 72 9 808
Total 10327 1418 71 42 171 20 1114
Number of HBsAg(+) women
1597 126 7 4 15 1 99
Percentage of women with HBsAg(+)
15.5% 8.9% 9.9% 9.5% 8.8% 5.0% 8.9%
Table 2: Age-specific prevalence of HBsAg (+) among pregnant women born in Taiwan and other Southeast Asia countries
Taiwan Southeast Asia Southeast Asia vs. Taiwan
HBsAg(+)/Total (%) HBsAg(+)/Total (%) OR (95% CI) P-value
Total 1597/10327 (15.5 %) 126/1418 (8.9 %) 0.53 (0.44–0.65) <0.001
Age (year)
20 173/1354 (12.8 %) 37/332 (11.1 %) 0.86 (0.59–1.25) 0.420
>20–25 579/3705 (15.6 %) 60/760 (7.9 %) 0.46 (0.35–0.61) <0.001
>25–30 530/3372 (15.7 %) 22/245 (9.0 %) 0.53 (0.34–0.83) 0.005
>30 315/1896 (16.6 %) 7/81 (8.6 %) 0.48 (0.22–1.04) 0.063
Date of birth
Before July 1984 1570/10021 (15.7 %) 107/1273 (8.4 %) 0.49 (0.40–0.61) <0.001
before 1970 285/1909 (14.9 %) 3/48 (6.3 %) 0.38 (0.12–1.23) 0.11
1970- before 1978 900/5335 (16.9 %) 34/310 (11.0 %) 0.61 (0.42–0.87) 0.007
1978- before July 1984 385/2777 (13.9 %) 70/915 (7.7 %) 0.52 (0.39–0.67) <0.001
July, 1984 and after 27/306 (8.8 %) 19/145 (13.1 %) 1.56 (0.84–2.91) 0.163
July, 1984 – June, 1986 24/210 (11.4 %) 17/138 (12.3 %) 1.09 (0.56–2.11) 0.80
July, 1986 and after 3/96 (3.1 %) 2/7 (28.6 %) 12.4 (1.67–91.87) 0.04a
a : P-value of Fisher's exact testBMC Public Health 2008, 8:49 http://www.biomedcentral.com/1471-2458/8/49
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52.4%) than other Asian women. The HBeAg(+)/
HBsAg(+) ratios declined over age, from 54.3% for Tai-
wanese women aged 20 years to 19.5% for those aged
>30 years and 56.8% for Southeast Asian women aged
20 years to 28.6% for those age>30 years. Except for
women 20 years old or below, women with positive
HBsAg results from the five other countries seemed to
have a higher HBeAg positive rate than Taiwanese women,
though the statistical significance was only reached for the
women aged >25–30 years or the women born before
July, 1984.
Discussion
In this study, we found that the positive rate of HBsAg
among pregnant Taiwanese women to be significantly
higher than that of the pregnant women from the five
other Southeast Asian countries, but the difference disap-
peared in those born in and after July, 1984. The HBeAg
positive rates in women with HBsAg seropositivity
appeared to be higher in women from other countries
than in Taiwanese women, especially for those aged of
>25 to 30 years.
The national vaccination program has successfully pre-
vented the vertical transmission from mother to child and
reduced the incidence and mortality of hepatocellar carci-
noma in Taiwan [1,6,7,9-11]. In that program, infants
were vaccinated with four doses of plasma-derived vaccine
at 0, 1, 2, and 12 months. In Nov. 1992 the plasma-
derived vaccine was replaced by three-dose recombinant
yeast vaccine at ages 0, 1 and 6 months. At the same time,
all pregnant women were screened for HBsAg, and
women with HBsAg positive serum were further tested for
HBeAg. Newborns of highly infectious carriers mothers,
who were found positive for both HBsAg and HBeAg, fur-
ther received hepatitis B immune globulin at birth [1].
After 15 years, the prevalence of HBsAg among persons
younger than fifteen years old dropped from 9.8% in
1984 to 0.7% in 1999[9]. Studies have also reported the
incidence of hepatocellular carcinoma among the chil-
dren born after the initiation of vaccination to be signifi-
cantly lower than those born before 1984 and have
suggested that the program has further prevented liver
cancer induced by HBV [6].
Our findings further suggest that the nationwide vaccina-
tion program is not only just successful at preventing
mother-to-child infection but might also have started to
benefit the second generation indirectly through by reduc-
ing the rates of maternal carriers. The pregnant women
born in July, 1984 or after were at lower risk of HBV infec-
tion and, therefore, less likely to continue the vertical
transmission than those born before July, 1984. This
decreasing trend was found in Taiwan women only in this
study and, hence, women born in other Southeast Asian
countries could serve as a natural comparison group rep-
resenting those who had not received vaccinations at birth
in this study. While the Southeast Asian sample had
increase in HBsAg positive rates (8.4% to 13.1%), the Tai-
wanese women had drop (15.7% to 8.8%). We further
stratified our data by the time periods representing differ-
ent coverage strategies (July, 1984 to June 1986, covering
newborns of HBV carriers and July, 1986 and after, cover-
ing all newborns) and found an 11.4% HBV infection rate
in women born during the earlier period, and found a
3.1% HBV infection rate in women born during that later
Table 3: Age-specific prevalence of HBeAg (+) among HBsAg(+) women born in Taiwan and other Southeast Asia countries
Taiwan Southeast Asia Southeast Asia vs. Taiwan
HBeAg(+)/HBsAg(+) (%) HBeAg(+)/HBsAg(+) (%) OR (95% CI) P-Value
Total 513/1597 (32.1 %) 66/126 (52.4 %) 2.32 (1.61–3.35) <0.001
Age (year)
20 94/173 (54.3 %) 21/37 (56.8 %) 1.10 (0.54–2.26) 0.789
>20–25 219/579 (37.8 %) 29/60 (48.3 %) 1.54 (0.90–2.62) 0.114
>25–30 139/530 (26.2 %) 14/22 (63.6 %) 4.92 (2.02–11.99) <0.001
>30 61/315 (19.4 %) 2/7 (28.6 %) 1.67 (0.32–8.79) 0.548
Date of birth
Before July, 1984 496/1570 (31.6 %) 54/107 (50.5 %) 2.21 (1.49–3.27) <0.001
before 1970 56/285 (19.6 %) 0/3 (0 %) -- --
1970- before 1978 274/900 (30.4 %) 22/34 (64.7 %) 4.19 (2.04–8.58) <0.001
1978- before July 
1984
166/385 (43.1 %) 32/70 (45.7 %) 1.11 (0.67–1.85) 0.687
July, 1984 and after 17/27 (63.0 %) 12/19 (63.2 %) 1.01 (0.30–3.40) 0.989
July, 1984 – June, 
1986
14/24 (58.3 %) 10/17 (58.8 %) 1.02 (0.29–3.60) 0.975
July, 1986 and after 3/3 (100 %) 2/2 (100 %) - -BMC Public Health 2008, 8:49 http://www.biomedcentral.com/1471-2458/8/49
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period. Although this finding might be confounded by
age, it would support the idea that coverage of all new-
borns is more effective than coverage for newborns of
HBV carrier mothers only.
In several low endemic regions, the immigrants from
other highly endemic regions have been reported to have
high prevalence of HBsAg, suggesting that the immigra-
tion patterns might introduce the challenges from hepati-
tis B infection in those countries. In the United Kingdom,
for example, a survey of 117 Chinese residents and 234
non-Chinese controls reported the 12.8% of Chinese and
0.4% non-Chinese residents were HBsAg positive persons
[12]. In France, an investigation of pregnant women
screened for HBsAg found that positive results in 0.29% of
the women of French origin, 7.15% of Southeast Asian
origin, and 6.52% for Sub Saharan African origin [13]. In
the USA, that HBsAg positivity was found in 5.8% of the
Asians (11.1% for Cambodian and 10.4% for Chinese),
1.0% of black non-Hispanics, 0.6% of white non-Hispan-
ics and 0.1% of Hispanics, suggesting that immigration
and migration patterns might have a detrimental impact
on public health with regard to HBV infection [14].
The difference in HBV infection rates in Taiwan and other
Southeast Asian countries are not as significant as those
from low endemic regions like in USA and France, and
their immigrants. In fact, these pregnant Southeast Asian
women even had slightly lower HBsAg positive rate than
the Taiwanese women. However, the Southeast Asian
women in this study might not have received vaccinations
in the same period in their countries of origin, as reflected
in the higher prevalence of HBsAg among these Southeast
Asian women than that of among Taiwanese women born
in 1984 or after. Hence, the increasing number of preg-
nant women from other Southeast Asian countries, mak-
ing up1.2% of our total in 1996–1999 and 24.6% in
2003–2005, might attenuate the indirect beneficial effects
of vaccination program on the second generation.
Moreover, we found the HBeAg positive rates seemed to
be significantly higher in the Southeast Asian women
(52.4%) who tested positive for HBsAg than in Taiwanese
women (32.1%). HBeAg is a seromarker related to infec-
tive HBV particles and its seropositivity might represent a
high level of viral replication in hepatocytes. Those, who
are positive for HBsAg and seropositive for HBeAg have
been reported to be more likely to develop hepatocellar
carcinoma and chronic liver disease [15-17]. Therefore,
the presence of the less spontaneous HBeAg seroconver-
sion among these Southeast Asian women might suggest
that they are more likely to develop severe liver disease in
the future. Furthermore, it would suggest that an increas-
ing number of newborns are being born to highly infec-
tious maternal carriers, who have been tested positive for
both HBeAg and HBsAg. The newborn children of these
women would not only need to be administered expen-
sive hepatitis B immune globulin at birth but they are also
less protected by the vaccination program than the chil-
dren born to low infectious maternal carriers [1,7].
Recently, several antiviral therapies, including interferon
and Lamivudine, have been proved to effectively reduce
the serum HBV DNA levels and increase the HBeAg sero-
conversion rates [18,19]. Hence, in addition to using the
HBV vaccine to reduce the hepatitis B infection to prevent
the severe liver diseases and vertical transmission at pri-
mary level, early screening of these migrant women and
other high risk populations can help identify high-risk
patients who might benefit from antiviral treatment
before pregnancy.
The potential modifiable factors associated with the dif-
ferent rates in HBeAg seroconversion is also worthy of fur-
ther exploration. One previous study in Taiwan reported
that the mean ratios of HBeAg/HBsAg declined steadily
from 1993 to 2000, with the mean average annual
declines in HBeAg rate being 1.2%, 0.6%, 0.4% and 0.1%
in those <26 years, 26–30 years, 31–35 years and >35
years, respectively [20]. The reason for this secular trend
was still unclear, since there were no related health pro-
grams being performed during this period.
Age and treatment of HBV might be associated with
HBeAg seroconversion but neither of them seemed to be
able to explain the differences in seroconversion rates in
this study [15,17,20]. Although the HBeAg positive rates
decreased with age, the age-specific HBeAg positive rates
for the Southeast Asian women were consistently higher
than those of the Taiwanese women above the age of 20
years. During prenatal examination, none of these preg-
nant women reported have received any previous treat-
ment for hepatitis B infection.
The genotypes of hepatitis B virus might be related to
HBeAg positive rates. HBV can be classified into several
genotype (A, B, C, D, E, F and G), which often vary in dif-
ferent geographical areas [21-23]. The dominant geno-
types in Taiwan and the five Southeast Asian countries in
this study are B and C [21,24]. It has been suggested that
genotype C patients have a have a longer delay in HBeAg
seroconversion in the immune clearance phase of chronic
HBV infection than genotype B patients [25,26]. Further
analysis is needed to explore the possible association
between genotype and different HBeAg seroconversion
rates in these populations.
One limitation of this study is that we did not collect indi-
vidual histories of vaccination and blood samples for test-
ing antibodies to HBsAg and HBcAg. Hence, we could not
directly analyze the influence of vaccination or efficacy ofBMC Public Health 2008, 8:49 http://www.biomedcentral.com/1471-2458/8/49
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vaccination on HBsAg and HBeAg status at individual
level. Instead, we considered Taiwanese women born dur-
ing the period vaccination program was being vaccinated,
since the coverage rates at that time were more 90% [4].
The countries from which other groups of pregnant
women arrived waited until a much later to implement
vaccination programs. For example, Vietnam introduced
the vaccine in pilot areas in 1997 and nationally in 2003
and Cambodia implemented the program in four health
centers only in 2001 but not yet nationally until 2005 [8].
Furthermore, the misclassification of vaccine experience is
more likely to attenuate the findings of this study.
That the tests for HBsAg and HBeAg were performed in the
prenatal examination is another limitation. There is pos-
sibility that these women from other countries might have
been infected after moving into Taiwan since they have
lived in Taiwan for a certain period. However, the preva-
lences of HBsAg among women in this study were similar
to other reports conducted in these countries, suggesting
that this limitation should not introduce appreciable bias
to our results. The findings of this study and other studies
were 9.9% vs. 2.0–16.5% for Philippines, 9.5% vs. 9.1%
for Cambodia, 8.8% vs. 6.2 – 8.8% for Indonesia, 5.0%
vs. 8.2%–10.3% for Thailand, and 8.9% vs. 9–16% for
Vietnam [27-35].
Conclusion
The lower HBsAg positive rate among Taiwanese women
born after July, 1984 suggests that the vaccination pro-
gram has effectively reduced the hepatitis B infection
among Taiwan women of child-bearing age and further
started to indirectly prevent hepatitis B infection in the
second generation, compared with women from other
Southeast Asian countries. These immigrants also had
higher HBeAg(+)/HBsAg(+) ratios, which might result in
more severe health outcomes and more expensive but less
efficient vaccination program. Hence, the increasing
number of foreign brides from Southeast Asian countries
will likely lessen the positive impact of this vaccination
program and should be further assessed.
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